New hope for inoperable liver cancer: triple therapy aims to unlock surgery
NCT ID NCT07483359
Summary
This study is testing a three-part treatment for a severe form of liver cancer that has spread into a major vein, making patients ineligible for surgery. The goal is to see if combining chemotherapy delivered directly to the liver, a targeted pill, and an immunotherapy drug can shrink the tumors enough to allow for potentially curative surgery. The study will enroll 38 patients to see how many become eligible for this surgery after treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Hospital of China Medical University
Shenyang, Liaoning, 110000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.